Invivyd vs Kymera Therapeutics
IVVD and KYMR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IVVD and KYMR compare
Kymera Therapeutics is the larger company, worth 68 times as much as Invivyd ($10.7B against $158M).
Kymera Therapeutics grew revenue faster over the last twelve months (134% versus 26.3% for Invivyd).
Invivyd keeps more of each dollar of sales as profit, with a net margin of −184% compared with −342% at Kymera Therapeutics.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IVVD | KYMR |
|---|---|---|
| Size and price | ||
| Market cap | $158M | $10.7B |
| Share price | $0.538 | $125.85 |
| Change, 1 year | −69.6% | 97.8% |
| Change, 5 years | −97.9% | 134% |
| Beta (5Y) | 2.47 | 0.54 |
| Employees | 122 | 238 |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 3 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 0 | 2 (better) |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.7× (better) | 105× |
| P/B | 0.9× (better) | 6.7× |
| FCF yield | −69.2% | −2.7% (better) |
| Fair value | $0.983 | $36.91 |
| Margin of safety | 45.3% (better) | −241% |
| Growth | ||
| Revenue growth (TTM) | 26.3% | 134% (better) |
| Revenue growth, 5Y average | – | 2.9% |
| Profitability | ||
| Gross margin | – | 0.00% |
| Operating margin | −193% (better) | −396% |
| Net margin | −184% (better) | −342% |
| FCF margin | −188% (better) | −283% |
| Return on equity | −95.9% | −27.3% (better) |
| Return on invested capital | −616% | −59.0% (better) |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 5.87 | 11.13 (better) |
| Altman Z-score | −4.74 | 41.07 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −0.24% | – |
| Shareholder yield | −0.24% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 79.0% | 114% |
| Held by insiders | 16.7% | 38.3% |
| Insider net buying, 12 months | −$531K (better) | −$301M |
| Short interest, % of float | 14.7% | 16.0% |
Go deeper
- IVVD stock overview
- IVVD income statement
- IVVD valuation and score
- KYMR stock overview
- KYMR income statement
- KYMR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.